Showing results (1861-1870 of 2,317) with videos related to

Sort By:
Pageof 232
Oncology Letters|April 17, 2019
Randomized controlled trial of lobaplatin plus etoposide vs. cisplatin plus etoposide as first-line therapy in patients with extensive-stage small cell lung cancerYing Cheng, Yun Fan, Xiaoqing Liu, et al.
World Journal of Pediatrics : WJP|June 3, 2011
Follow-up results of children with melamine induced urolithiasis: a prospective observational cohort studyJian Gao, Hong Xu, Xin-Yu Kuang, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|March 13, 2019
Inhibition of microRNA-124a attenuates non-alcoholic fatty liver disease through upregulation of adipose triglyceride lipase and the effect of liraglutide interventionQian-Hua Fang, Qi-Ling Shen, Jin-Jin Li, et al.
Advanced Materials (Deerfield Beach, Fla.)|May 27, 2025
Optimizing Printed Quasi-2D Luminescent Perovskite Films via Delaminated Metal-Organic Framework ModulationShanjing Liu, Han Fang, Yahui Su, et al.
Scientific Reports|February 13, 2024
A pivotal bridging study of lurbinectedin as second-line therapy in Chinese patients with small cell lung cancerYing Cheng, Chunjiao Wu, Lin Wu, et al.
Cancer Medicine|April 12, 2024
Outcomes after fertility-sparing surgery of early-stage ovarian cancer: A nationwide population-based studyChia-Yi Lee, Chun-Ju Chiang, Yi-Jou Tai, et al.
Journal of Medicinal Chemistry|March 19, 2025
Synthesis of an RBM39 Degrader That Downregulates CEP192 and Induces Disorganized Spindle StructuresXilin Lyu, Xiancheng Wang, Dongze Lin, et al.
British Journal of Cancer|February 14, 2018
Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)Baohui Han, Kai Li, Yizhuo Zhao, et al.
Plos One|September 3, 2011
Genetic variants in MARCO are associated with the susceptibility to pulmonary tuberculosis in Chinese Han populationMai-Juan Ma, Hai-Bing Wang, Hao Li, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2015
Anti-angiogenic-specific adverse events in patients with non-small cell lung cancer treated with nintedanib and docetaxelMartin Reck, Anders Mellemgaard, Joachim von Pawel, et al.
Pageof 232